MCLA-128 is expected to directly inhibit tumor growth by blocking HER2:HER3 signaling and, through the ADCC mechanism, eliminate tumor cells via recruitment of natural killer effector cells to tumor cells coated with MCLA-128. The gene discussed is ERBB3; the disease is neoplasm.